GOSS - Gossamer Bio Inc Stock Price, Fair Value and News

$0.700.00 (0.00%)

Delayed as of 21 Nov 2024, 10:01 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GOSS Price Action

Last 7 days

-14.6%

Last 30 days

-23.9%

Last 90 days

-21.3%

Trailing 12 Months

-7.9%

GOSS RSI Chart

GOSS Valuation

Market Cap

158.6M

Price/Earnings (Trailing)

-2.21

Price/Sales (Trailing)

127.4

EV/EBITDA

-2.56

Price/Free Cashflow

-112.42

GOSS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GOSS Fundamentals

GOSS Revenue

Revenue (TTM)

1.6M

Rev. Growth (Qtr)

-90.11%

GOSS Earnings

Earnings (TTM)

-71.6M

Earnings Growth (Yr)

23.01%

Earnings Growth (Qtr)

-162.57%

GOSS Profitability

EBT Margin

-3839.04%

Return on Equity

-132.35%

Return on Assets

-20.42%

Free Cashflow Yield

-0.89%

GOSS Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

-0.18

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	966.5K	1.2M	1.4M	1.6M
2021	2.8M	2.1M	1.4M	761.0K
2020	5.0M	4.5M	4.0M	3.4M
2019	0	0	0	5.6M
2018	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

CEO	Mr. Faheem Hasnain
WEBSITE	gossamerbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	178

Gossamer Bio Inc Frequently Asked Questions

What is the ticker symbol for Gossamer Bio Inc? What does GOSS stand for in stocks?

GOSS is the stock ticker symbol of Gossamer Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gossamer Bio Inc (GOSS)?

As of Wed Nov 20 2024, market cap of Gossamer Bio Inc is 158.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GOSS stock?

You can check GOSS's fair value in chart for subscribers.

Is Gossamer Bio Inc a good stock to buy?

The fair value guage provides a quick view whether GOSS is over valued or under valued. Whether Gossamer Bio Inc is cheap or expensive depends on the assumptions which impact Gossamer Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GOSS.

What is Gossamer Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, GOSS's PE ratio (Price to Earnings) is -2.21 and Price to Sales (PS) ratio is 127.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOSS PE ratio will change depending on the future growth rate expectations of investors.